A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer
Fase: Phase II-III clinical trials
Struttura Principale: Oncologia Medica Toraco-Polmonare
Farmaco: MK2870 (sacituzumab tirumotecan)
Pembrolizumab
Chemotherapy
Patologie: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
PI: Dr. Giuseppe Lo Russo
This trial is testing MK2870 (sacituzumab tirumotecan) administered in combination with pembrolizumab in people with squamous non-small cell lung cancer (NSCLC).
During the Induction Period, all participants will receive pembrolizumab plus chemotherapy. Carboplatin, paclitaxel and nab-paclitaxel are standard treatments for NSCLC.
After the Induction Period, they will move on to the Maintenance Period:
- Group 1 will receive MK-2870 plus pembrolizumab.
- Group 2 will receive pembro as monotherapy.
Last update: 20/05/2025